Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort

Thomas Höfner, Sonia Vallet, Boris A Hadaschik, Sascha Pahernik, Stefan Duensing, Markus Hohenfellner, Dirk Jäger, Carsten Grüllich

Publikation: Beitrag in Fachzeitschrift (peer-reviewed) › Artikel in Fachzeitschrift

5 Zitate (Scopus)

Fingerprint

Untersuchen Sie die Forschungsthemen von „Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort“. Zusammen bilden sie einen einzigartigen Fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science